Biotricity is revolutionizing cardiac care with its cutting-edge remote diagnostic and monitoring solutions that cater to a $35 billion total addressable market opportunity. By integrating advanced hardware and proprietary software, Biotricity has established a new paradigm in cardiac care. The Company’s robust technology platform and product ecosystem, featuring FDA-cleared smart cardiac monitors, coupled with a comprehensive cloud ecosystem, ensure seamless management of patient health across all stages of cardiac care. Utilized daily by cardiologists across 34 states and 500 centers, Biotricity has captured an 8% market share in cardiology, bolstered by a remarkable 99.2% retention rate and an LTV/CAC ratio of 9.
Biotricity reported record margins of 69% in FY2Q24 and expects margins to improve to 80% in the near-term. The Company’s revenue run rate, which was $14 million as of September 30, 2023, is expected to increase to $20 million over the next 12 months as Biotricity’s strategic partnerships with leading Integrated Delivery Networks (IDNs) and Group Purchasing Organizations (GPOs) are set to accelerate growth. Significantly, 93% of the Company’s trailing 12-month revenue is recurring, thanks to its technology-as-a-service model, paving a clear path to profitability with positive EBITDA anticipated in the next six months. Biotricity’s leadership team has over 100 years of collective startup experience and a proven track record of successfully launching 70+ products in over 30 countries. With its strong technological foundation, clear path to profitability, strategic market positioning, and experienced leadership, Biotricity represents a compelling value proposition for investors seeking to capitalize on the rapidly evolving medtech space.
Learn more: https://www.redchip.com/stocks/btcy
RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.
Biotricity (BTCY) is a client of RedChip Companies. BTCY agreed to pay RedChip Companies a $7,500 monthly cash fee, beginning in February 2024, and 60,000 warrants, with an exercise price of $1.40 and three-year term, for 6 months of RedChip investor awareness services. BTCY also agreed to pay RedChip a one-time fifty-thousand dollar fee for a 10-day national TV ad campaign aired weekdays from April 8 through April 19, 2024 and a forty-five thousand dollar fee for a 10-day national TV ad campaign aired weekdays from June 24 through July 8, 2024.
For full disclosure, visit RedChip.com/disclosures.
